Dr Adam Olszewski speaks to ecancer about a study presented at ASH 2024 evaluating mosunetuzumab SC plus polatuzumab vedotin versus rituximab plus polatuzumab vedotin in patients with relapsed or refractory (RR) large b-cell lymphoma (LBCL).

He explains that this was a randomised trial with 80 patients split 1:1 between either the experimental arm of mosunetuzumab SC plus polatuzumab vedotin or the control arm of rituximab plus polatuzumab vedotin.

Dr Olszewski reports that results were encouraging with the experimental arm seeing a total response rate of 77% compared to 50% in the control arm.